Heart safety check for new drug vicadrostat
NCT ID NCT07513207
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This study tests whether a single dose of vicadrostat changes heart rhythm in 45 healthy adults aged 18 to 50. Participants receive vicadrostat, placebo, and moxifloxacin (a known heart-affecting drug) in random order. The goal is to see if vicadrostat is safe for the heart before moving to patient trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Humanpharmakologisches Zentrum Biberach
RECRUITINGBiberach, 88397, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vicadrostat
What this could lead to
If successful, this study will confirm that vicadrostat is safe for the heart, allowing further testing for potential future treatments.
What could go wrong
This is an early phase 1 safety study in healthy people, not patients. It only checks heart effects, not whether the drug works for any disease.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.